Chai Discovery, a company that builds AI models to design antibodies, has closed a $400 million Series C round that brings its valuation to about $3.8 billion. Investors in the round include OpenAI, Sequoia, Kleiner Perkins and Index Ventures.
Chai‑3: roughly double the hit rate
The company introduced its new Chai‑3 model, which Chai Discovery says roughly doubles the molecular hit rate compared with prior approaches, bringing the success rate to approximately 35–40 percent. In practice this means a substantially higher proportion of model‑suggested candidates show promising activity against the intended molecular targets in early screening.
Major pharma deals: Pfizer, Eli Lilly, Novartis
Chai Discovery also announced a landmark licensing agreement with Pfizer and additional agreements with Eli Lilly and Novartis. These partnerships indicate that large pharmaceutical companies are willing to pay for AI‑driven molecule design and to incorporate such outputs into their drug discovery pipelines.
Why this matters: shrinking the search bottleneck
For decades the primary bottleneck in drug design was the vast search space of possible molecules — historically requiring testing of millions of compounds to find viable candidates. Chai Discovery argues that Chai‑3 substantially reduces that search burden by curating chemical space and delivering candidates that are more likely to progress from computational design to experimental validation.
Remaining challenge: clinical validation
Despite the improved hit rates, clinical validation remains the critical remaining hurdle. Proving that a computationally designed candidate is safe and effective in humans still follows established, time‑consuming, and risky clinical trial processes. In other words, AI has eased the hardest search problem in early discovery, but the clinic is the next major frontier.
Takeaway
The company’s funding round, elevated valuation, and agreements with Pfizer, Eli Lilly, and Novartis underscore a shift: AI‑designed molecules are moving from demonstrations toward integration in the pharmaceutical supply chain. The molecular search barrier has been reduced; the subsequent task is to translate those candidates successfully through clinical development.
